Wednesday, August 26, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDAAbbott's Dual Glucose-Ketone Monitor Wins FDA NodtodayDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Direct Win for Oracle, Pressure on Smaller Defense IT Rivals4 weeks agoHEALTHCARE & FDARegeneron's Gene Therapy Wins First GSD Type Ia ApprovaltodayTECHFCC Tightens Submarine Cable Licensing Rules—Tech Giants Face New Compliance Costs, Telecom Carriers Gain Regulatory Clarity4 weeks agoDEFENSEStryker Lands $100M Defense Contract—Combat Vehicle BoosttodayHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—UnitedHealth, Humana, and Anthem Positioned to Gain from Simplified Metrics4 weeks agoTRADE & TARIFFSWalmart Deploys $2.9B Tariff Refund Into Price CutstodayDEFENSEHouse Passes $1.15 Trillion Defense Bill—Lockheed, Raytheon, and General Dynamics Positioned for Record Spending4 weeks agoTRADE & TARIFFSTrump Lifts Ground Beef Tariffs—Ranchers Face Price PressuretodayDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Largest Defense IT Overhaul in Years4 weeks agoWHITE HOUSETrump Kills Affirmative Action Rules—Contractors Face Compliance ShiftyesterdayDEFENSERocket Lab Wins $266M Space Force Contract—Suborbital Launch Capability Becomes Defense Asset4 weeks agoHEALTHCARE & FDAFDA Clears Robotic Blood Draw—Phlebotomy Shortage EasesyesterdayHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—Big Insurers Win, Quality Metrics Tighten4 weeks agoWHITE HOUSELabor Dept Eases Disability Hiring Rules—Contractors Save Compliance CostsyesterdayDEFENSERocket Lab Wins $266M Space Force Missile Defense Contract—Suborbital Launch Niche Gets Federal Validation4 weeks agoWHITE HOUSELabor Dept Eases Veteran Hiring Rules—Contractors Cut ComplianceyesterdayDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Cloud Incumbents Face Pressure, Oracle Locks in Defense Revenue4 weeks agoTECHCHIPS Act Transforms Binghamton Into Semiconductor Hub2 days agoCRYPTOSEC Settles Coinbase FOIA Suit Over Missing Gensler Texts—Crypto Compliance Pressure Eases, Coinbase Stock Gains Clarity4 weeks agoTRADE & TARIFFSTrump Administration Targets Iran's Banking System With New Sanctions2 days agoHEALTHCARE & FDACMS Stars Redo Lifts Medicare Advantage Insurers—Rating System Overhaul Favors UnitedHealth, Humana, Anthem4 weeks agoTECHUtah Governor Signs Quantum Computing Initiative Order2 days agoDEFENSEPentagon Awards Largest F-35 Spare Parts Contract—Lockheed Locks in Sustainment Revenue4 weeks agoDEFENSEFAA Engine Inspection Order Lifts MRO Stocks3 days agoDEFENSEHouse Passes $1.15T Defense Bill—Lockheed, Raytheon, General Dynamics Lock in Revenue4 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings3 days agoMARKETSSEC Explores 23-Hour Stock Trading—Market Makers and Tech Platforms Get New Revenue4 weeks agoHEALTHCARE & FDATrump Vaccine Spacing Order Reshapes Pharma Demand3 days agoENERGYPHMSA Updates Pipeline Safety Standards—Compliance Costs Hit Operators, Benefit Inspectors4 weeks agoTECHD-Wave Wins Canadian Quantum Funding for Annealing3 days agoSEARCH DEMANDCasgevy List Price: $2.2 Million4 weeks agoENERGYEnbridge Wins Federal Permit for Line 5 Tunnel4 days agoSEARCH DEMANDData Center Power Exchange4 weeks agoENERGYFederal Court Orders Enbridge Line 5 Removal4 days agoTRADE & TARIFFSAmazon Gets $600M Tariff Refund—Retailers Lift Guidance on Windfall4 weeks agoWHITE HOUSEFinCEN Finalizes BOI Exemption for U.S. Persons4 days agoTECHCommerce Awards $874M in Semiconductor R&D LOIs—Chip Makers Get Federal Backing4 weeks agoHEALTHCARE & FDAGAO Finds $7.6B Medicare Hospice Overpayment5 days agoHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win3 weeks agoENERGYNewsom Passes Diablo Canyon Decision to Successor6 days agoDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenue3 weeks agoDEFENSERTX Lands Fresh Missile Defense Contract—Stock Undervaluedlast weekWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Market3 weeks agoTECHCommerce Eases Drone Export Rules—U.S. Makers Winlast weekHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruption3 weeks agoHEALTHCARE & FDAFDA Reclassifies Cancer Tests—Easier Path for Diagnosticslast weekENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risk3 weeks agoHEALTHCARE & FDAFTC Probes Epic Systems Over Health Records Monopolylast weekTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeeze3 weeks agoDEFENSETrump's $1.5T Defense Push Fuels Colorado Contractor Windfalllast weekHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Win3 weeks agoENERGYEPA Exempts Calcium Carbonate From Pesticide Tolerance—Farm Input Easeslast weekHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressure3 weeks agoWHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma Demandlast weekHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relief3 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face Pressurelast weekTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestone3 weeks agoTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings Boostlast weekDEFENSERising Defense Spending Lifts Northrop Grumman Outlook3 weeks agoENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks Pathlast weekMARKETSFTC Threatens Booking Holdings Over Priceline Practices3 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earningslast weekHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practices3 weeks agoCRYPTOSEC Delays Crypto Rules—Uncertainty Persistslast weekHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanoma3 weeks agoTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refundlast weekTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payout3 weeks agoTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makerslast weekTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backing3 weeks agoHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Winslast weekWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employers3 weeks agoDEFENSEBlackSky Lands Multi-Year Satellite Contractlast weekENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakes2 weeks agoTECHFCC Eases Broadband Label Rules—ISPs Win Flexibilitylast weekDEFENSEPentagon Awards Space-Based Target Tracking Contracts2 weeks agoDEFENSEIonQ Lands $28M U.S. Defense Quantum Contractlast weekTECHTrump Administration Adds 6 Chipmakers to U.S. Portfolio2 weeks agoHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock2 weeks agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty2 weeks agoENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask2 weeks agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains2 weeks agoHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance2 weeks agoWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift2 weeks agoWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing2 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare & FDA

Abbott's Dual Glucose-Ketone Monitor Wins FDA Nod

First wearable to track both metrics opens new revenue stream for continuous glucose monitoring leader.

Image: Money Racket
By at Money Racket · Aug 26, 2026

The FDA authorized Abbott's Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System on August 25, marking the first wearable device in the U.S. that continuously monitors ketone levels and the first globally to track both ketones and blood sugar together in a single device. The authorization covers patients aged 2 and older with diabetes.

Abbott's Libre Duo turns a feature gap into a moat—competitors now chase a moving target.

Who cashes in: Abbott (ABT) is the direct winner—the Libre franchise already dominates the continuous glucose monitoring (CGM) market, and adding ketone tracking creates a new clinical use case and potential pricing premium. Patients with diabetic ketoacidosis risk (particularly children and type 1 diabetics) now have a reason to upgrade or switch to Libre Duo. Suppliers to Abbott's sensor manufacturing—including component makers in diagnostics and wearable electronics—see incremental volume. No major competitor has a dual-metric wearable yet, so Dexcom (DXCM) and Medtronic (MDT) face a feature gap they'll need to close.

Who's exposed: Dexcom and Medtronic both lose share of the premium CGM segment if Libre Duo's ketone data becomes standard of care for high-risk diabetics. Medtronic's Guardian system and Dexcom's G7 lack ketone monitoring, forcing them to either acquire or develop the capability. The competitive moat widens for Abbott in a market where switching costs are high once patients and clinicians adopt a device.

What to watch next: Clinical adoption rates among pediatric endocrinologists and type 1 diabetes centers over the next 6–12 months. If ketone monitoring becomes reimbursed as a separate benefit or drives higher patient retention, Abbott's CGM revenue growth accelerates. Watch for Dexcom or Medtronic announcements on ketone-capable devices or partnerships.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://moneyracket.com/article/abbott-libre-duo-ketone-monitoring-fda/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →